Perspective Therapeutics (CATX) News Today $3.94 +0.17 (+4.38%) As of 02:30 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock CATX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a StudiesMay 18 at 6:30 AM | globenewswire.comLifeSci Capital Remains a Buy on Perspective Therapeutics (CATX)May 17, 2026 | theglobeandmail.comPerspective Therapeutics, Inc. (CATX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comPerspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 ResultsMay 11, 2026 | globenewswire.comPerspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of "Buy" by BrokeragesMay 10, 2026 | americanbankingnews.comPerspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of "Buy" from AnalystsMay 10, 2026 | marketbeat.comPerspective Therapeutics (CATX) Receives a Buy from Piper SandlerMay 7, 2026 | theglobeandmail.comPerspective Therapeutics Highlights Alpha-Targeted Oncology Strategy UpdateMay 6, 2026 | theglobeandmail.comWedbush Reaffirms Outperform Rating for Perspective Therapeutics (NYSEAMERICAN:CATX)May 5, 2026 | marketbeat.comPerspective Therapeutics (CATX) Expected to Announce Quarterly Earnings on MondayMay 4, 2026 | marketbeat.comPerspective Therapeutics: Decent Prospect In Radiopharmaceuticals FieldApril 27, 2026 | seekingalpha.comPerspective Therapeutics, Inc.: Perspective Therapeutics to Provide Several Upcoming Corporate UpdatesApril 24, 2026 | finanznachrichten.dePerspective Therapeutics, Inc. to Provide Corporate Updates and Financial Results in May 2026April 24, 2026 | quiverquant.comQPerspective Therapeutics to Provide Several Upcoming Corporate UpdatesApril 24, 2026 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Perspective Therapeutics (CATX) and UnitedHealth (UNH)April 23, 2026 | theglobeandmail.comPerspective Therapeutics Highlights Encouraging Interim Neuroendocrine Tumor DataApril 21, 2026 | theglobeandmail.comPerspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual MeetingApril 20, 2026 | globenewswire.comPerspective Therapeutics to Participate in Upcoming Investor ConferencesApril 2, 2026 | globenewswire.comPerspective Therapeutics, Inc. Announces Acceptance of [212Pb]VMT-α-NET Program Data for Presentation at 2026 AACR Annual MeetingMarch 17, 2026 | quiverquant.comQPerspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026March 17, 2026 | globenewswire.comPerspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 ResultsMarch 17, 2026 | finanznachrichten.dePerspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 ResultsMarch 16, 2026 | globenewswire.comPerspective Therapeutics Q4 2025 earnings previewMarch 13, 2026 | msn.comPerspective Therapeutics Raises Capital to Advance Radiopharmaceutical PipelineMarch 11, 2026 | theglobeandmail.comPerspective Therapeutics (CATX) Receives a Buy from JonesTradingFebruary 20, 2026 | theglobeandmail.comPiper Sandler initiates coverage of Perspective Therapeutics (CATX) with overweight recommendationFebruary 19, 2026 | msn.comPerspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial ProgressFebruary 17, 2026 | insidermonkey.comPerspective Therapeutics, Inc.: Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial ResultsFebruary 17, 2026 | finanznachrichten.dePerspective Therapeutics, Inc. to Report Full Year 2025 Financial Results and Business Update on March 16, 2025February 17, 2026 | quiverquant.comQPerspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial ResultsFebruary 17, 2026 | globenewswire.comBuy Rating on Perspective Therapeutics (CATX) Driven by Differentiated Radiopharmaceutical Platform and Undervalued Long-Term UpsideFebruary 17, 2026 | tipranks.comPerspective Therapeutics (CATX) Is Up 92.6% After $175M Equity Raise To Fund Targeted Alpha Therapies – Has The Bull Case Changed?February 4, 2026 | finance.yahoo.comPerspective Therapeutics shares rise after $175 million offeringFebruary 2, 2026 | au.investing.comPerspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsFebruary 2, 2026 | globenewswire.comPerspective Therapeutics Highlights Progress in Radiopharmaceutical PipelineFebruary 2, 2026 | tipranks.comA Look At Perspective Therapeutics (CATX) Valuation After New VMT-α-NET Trial And Pipeline UpdatesFebruary 2, 2026 | finance.yahoo.comPerspective Therapeutics: VMT-A-NET Presses On In SSTR2-Solid Tumor Targeting SpaceJanuary 30, 2026 | seekingalpha.comAnalysts Are Bullish on These Healthcare Stocks: MannKind (MNKD), Perspective Therapeutics (CATX)January 27, 2026 | theglobeandmail.comPerspective Therapeutics, Inc. (CATX) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 14, 2026 | seekingalpha.comPerspective Therapeutics Highlights Progress in Radioligand Oncology PipelineJanuary 14, 2026 | tipranks.comPerspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare ConferenceJanuary 12, 2026 | finance.yahoo.comPerspective Therapeutics outlines 2026 clinical and manufacturing prioritiesJanuary 12, 2026 | tipranks.comPerspective Therapeutics Reports Positive Interim Neuroendocrine Tumor DataJanuary 9, 2026 | tipranks.comPerspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers SymposiumJanuary 9, 2026 | globenewswire.comPerspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceDecember 18, 2025 | globenewswire.comPerspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers SymposiumDecember 4, 2025 | markets.businessinsider.comPerspective Therapeutics Updates Corporate Presentation on AdvancementsDecember 1, 2025 | tipranks.comPerspective Therapeutics assumed with a Buy at TruistNovember 24, 2025 | msn.comUBS Maintains Perspective Therapeutics (CATX) Buy RecommendationNovember 22, 2025 | msn.comPerspective Therapeutics price target lowered to $7 from $18 at UBSNovember 21, 2025 | msn.com Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CATX Media Mentions By Week CATX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CATX News Sentiment▼0.000.39▲Average Medical News Sentiment CATX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CATX Articles This Week▼23▲CATX Articles Average Week Get the Latest News and Ratings for CATX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Perspective Therapeutics and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ENOV News PRCT News EYE News CDRE News KMTS News INSP News AVNS News AORT News IRMD News CNMD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:CATX) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
